Shanghai Fosun Pharmaceutical : OVERSEAS REGULATORY ANNOUNCEMENT (H SHARES)

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥（集 團）股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The following sets out the "Announcement in Relation to the Progress of Drug Clinical Trials of a Subsidiary" published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "Company") on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, the PRC

19 January 2022

As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin and Ms. Guan Xiaohui; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

• for identification purposes only

Stock code: 600196 Stock abbreviation: Fosun Pharma Announcement No.: Lin 2022-015

Bond code: 136236 Bond abbreviation:16 Fosun 01

Bond code: 143020 Bond abbreviation:17 Fosun 01

Bond code: 143422 Bond abbreviation:18 Fosun 01

Bond code: 155067 Bond abbreviation:18 Fosun 02

Bond code: 155068 Bond abbreviation:18 Fosun 03

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* Announcement in Relation to the Progress of Drug Clinical Trial by a Subsidiary

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and severally and jointly accept full responsibility for the truthfulness, accuracy and completeness of this announcement.

I. Overview

Jiangsu Wanbang (Group) Biopharmaceutical Co., Ltd. *(江蘇萬邦生化醫藥集團有 限責任公司) ("Jiangsu Wangbang"), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥(集團)股份有限公司) (the "Company"), recently commenced phase III clinical trial on SAF-189 (i.e., the foritinib succinate capsules, hereinafter the "Investigational New Drug") for the treatment of non-small cell lung cancer (ALK+) in the PRC (excluding Hong Kong and Macau Special Administrative Regions and Taiwan Region, the same below).

II. Research Progress of the Investigational New Drug

The Investigational New Drug is an innovative small molecule chemical drug and is intended to be used primarily for the treatment of tumors. The Investigational New Drug is subject to joint pre-clinical studies by Chongqing Fochon Pharmaceuticals, Ltd.* (重慶

1

復創醫藥研究有限公司), a subsidiary of the Company, and Shanghai Institute of Materia Medica Chinese Academy of Sciences, and Jiangsu Wanbang was granted the exclusive rights to develop (including but not limited to clinical trials and registration) and commercialize the Investigational New Drug.

As at the date of this announcement, drugs for the treatment of non-small cell lung cancer (ALK+) marketed in the PRC includes Crizotinib Capsules of Prifer Inc., Ceritinib Capsules of Novartis AG, Ensartinib Capsules of Betta Pharmaceuticals Co., Ltd. *(貝達 藥業股份有限公司) and Alectinib Capsules of Roche. According to the latest data from IQVIA CHPA (provided by IQVIA, a global leading provider of professional information and strategic consulting services for the pharmaceutical and health industry; IQVIA CHPA data represents the sales market of drugs for hospitals with over 100 beds in the PRC. The actual sales of different drugs may vary from the IQVIA CHPA data in varying degrees due to the differences in their respective sales channels), the sales of drugs above in the PRC amounted to approximately RMB1.825 billion in 2020 and RMB1.145 billion in first half of 2021, respectively.

As at December 2021, the Group's cumulative investment in the R&D of the Investigational New Drug amounted to RMB178.97 million (unaudited).

III. Risk Reminder

Based on our drug development experience, here are certain risks underlying the R&D of new drugs. For example, clinical trials may be terminated due to issues such as safety and/or efficacy.

As required by the relevant laws and regulations in the PRC, the Investigational New Drug is subject to a series of clinical studies and approval by the relevant national drug review department in the PRC before it can be marketed.

The R&D and marketing of new drugs is a long-term task involving various uncertainties. Investors are advised to take note of the investment risks.

Announcement is hereby given.

2

The board of directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* 19 January 2022

3